Ritter Pharmaceuticals , Inc. engages in the development of novel therapeutic products which modulate the human gut microbiome to treat gastrointestinal diseases. It focuses on the development and commercialization of RP-G28.
Sign Up for our 100% Free Email Newsletter:
Text Message Alerts ---> text 'PS101' to 67076
(It's FREE, however Msg&Data rates may apply.)